Business
bioAffinity Technologies Adds to Growing Number of Case Studies Demonstrating Clinical Value of CyPath® Lung
SAN ANTONIO, September 26, 2025--bioAffinity Technologies shares 3 new case studies in which CyPath Lung detected Stage 1A lung cancer or prevented unnecessary invasive procedures.
About this update from Bioaffinity Technologies, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":201,"url":"https://media.zenfs.com/en/business-wire.com/43eff3069dd9cef58ee3e7bf2e2f5f30"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/LbxMcwaqvY7zwFgHoqH_Og--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQwMjtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/43eff3069dd9cef58ee3e7bf2e2f5f30","width":480,"height":201}},"lazy":false},{"type":"text","content":"Noninvasive diagnostic test again leads to detecting Stage 1A lung cancer","length":73,"tagName":"p","attribs":{}},{"type":"text","content":"SAN ANTONIO, September 26, 2025--(BUSINESS WIRE)--bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company advancing noninvasive diagnostics for lung cancer and other lung diseases, today released three additional case studies – one in which use of CyPath® Lung led to detecting lung cancer at Stage 1A, its earliest and possibly curative stage, and two where risky invasive procedures were avoided for patients facing difficult healthcare choices.","length":469,"tagName":"p"},{"type":"text","content":""These three new cases, provided by a Texas pulmonologist who has been using CyPath® Lung for more than a year, reflect what we're hearing from many physicians – CyPath® Lung enhances clinical decision-making by personalizing care and playing a critical role in refining the diagnostic pathway," said Dr. Gordon Downie, Chief Medical Officer of bioAffinity Technologies. "We believe CyPath® Lung can be a transformative tool in the lung cancer diagnostic pathway, especially when imaging results are inconclusive. A positive CyPath® Lung result can lead to earlier diagnosis and treatment, and a negative result can spare patients from unnecessary invasive procedures."","length":693,"tagName":"p"},{"type":"text","content":"Patient Case Study Highlights","length":29,"tagName":"p"},{"type":"text","content":"Case Study "Samuel": Prompting Action in a Hesitant Patient Led to Detecting Stage 1A Lung CancerThis 68-year-old smoker's CT showed a 1.8 cm spiculated lesion in the right upper lobe. The nodule was categorized as suspicious but relatively low risk for malignancy. The patient was hesitant to undergo a biopsy. However, a positive CyPath® Lung result...